Equities

Qingdao NovelBeam Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Qingdao NovelBeam Technology Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)47.36
  • Today's Change-0.64 / -1.33%
  • Shares traded927.65k
  • 1 Year change+19.29%
  • Beta0.5987
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Qingdao NovelBeam Technology Co Ltd is a China-based company principally engaged in the research and development, production and sales of medical endoscopic equipment and optical products. Its main products of medical endoscope equipment include fluorescent endoscopes, fluorescent camera adapters/adaptive lenses, fluorescent light source modules and white light source modules. Its medical endoscopic equipment products are mainly used in abdominal endoscopic surgery such as liver and gallbladder and gastrointestinal surgery. Its optical products mainly include medical optical products, industrial and laser optical products, and biometric products. Among them, the biometric products include fingerprint devices, palmprint devices and related accessories. In addition, the Company also provides technical services and house leasing services. The Company distributes its products both in the domestic market and to overseas markets.

  • Revenue in CNY (TTM)571.80m
  • Net income in CNY174.33m
  • Incorporated2003
  • Employees841.00
  • Location
    Qingdao NovelBeam Technology Co LtdNo.100 Keyuanwei 4th RoadLaoshan DistrictQINGDAO 266100ChinaCHN
  • Phone+86 53 288706015
  • Fax+86 53 288705263
  • Websitehttps://www.novelbeam.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hangzhou Ags Medtech Co Ltd668.70m272.95m4.92bn744.0018.011.98--7.363.373.378.2530.670.26733.3111.94898,793.6010.91--11.39--69.67--40.82--18.27--0.001--25.14--35.06------
Zhejiang Orient Gene Biotech Co Ltd842.11m-479.50m4.97bn2.28k--0.7816--5.90-2.48-2.484.3731.550.1071.443.39369,997.60-6.6821.19-7.7726.7434.8858.52-62.4332.423.86--0.046224.780.94617.65-33.06--138.80--
Assure Tech (Hangzhou) Co Ltd462.72m120.87m4.99bn741.0041.290.9667--10.790.95110.95113.6440.620.08092.222.17624,449.302.1123.692.3028.0130.3264.6126.1147.6511.28--0.001218.787.4220.8535.8528.6963.16--
Nanjing Vishee Medical Technology Co Ltd433.83m125.95m5.49bn639.0043.583.31--12.651.321.324.5317.310.24114.0014.42678,922.307.008.397.639.2061.2471.6229.0332.766.54--0.018259.13-13.454.64-25.160.447439.73--
SWS Hemodialysis Care Co Ltd733.59m113.43m5.52bn1.10k48.793.13--7.520.35380.35382.295.520.35772.806.23665,688.205.235.685.836.5445.7145.7914.6116.065.25--0.001428.46-17.8031.86-63.55--24.70--
Jiangsu Bioperfectus Technologies Co Ltd339.03m-25.96m5.66bn592.00--1.91--16.70-0.3096-0.30964.0435.380.09031.856.13572,683.70-0.691920.36-0.79624.5558.2262.71-7.6631.893.22--0.132928.76-13.293.9099.46---9.88--
Qingdao NovelBeam Technology Co Ltd571.80m174.33m5.68bn841.0032.624.31--9.931.451.454.7610.990.38170.99325.67679,901.1011.3912.7012.6114.1164.3463.1529.8433.963.4351.040.105840.95-5.9011.86-7.1113.4813.44--
Shanghai Aohua Phtlctrcty Endscp Co Ltd671.62m-72.38m5.69bn1.22k--4.57--8.48-0.5475-0.54755.109.250.38341.022.29552,775.60-4.143.01-5.153.3461.7968.86-10.807.521.57--0.208643.3010.5420.28-63.68-16.8623.29--
Shenzhen Lifotronic Technology Co Ltd1.05bn251.02m5.85bn1.67k23.112.78--5.550.59070.59072.474.900.38552.515.74631,202.608.9814.0312.1017.3461.0362.4623.3027.253.00--0.140639.010.202422.125.1227.99-1.6318.64
Hangzhou Biotest Biotech Co Ltd478.69m102.57m6.01bn603.0057.812.57--12.560.69640.69643.0615.660.19133.205.70793,854.104.0223.634.2526.2050.5756.5921.0041.4713.08--0.0000834.4226.5321.7859.0143.1244.08--
Data as of Feb 13 2026. Currency figures normalised to Qingdao NovelBeam Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

22.69%Per cent of shares held by top holders
HolderShares% Held
Orient Securities Asset Management Co. Ltd.as of 30 Jun 202510.32m13.72%
GF Fund Management Co., Ltd.as of 30 Jun 20253.17m4.22%
Cinda Fund Management Co. Ltd.as of 30 Jun 2025871.81k1.16%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025589.36k0.78%
New China Fund Management Co., Ltd.as of 30 Jun 2025523.53k0.70%
Galaxy Asset Management Co., Ltd.as of 30 Jun 2025501.14k0.67%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025381.45k0.51%
E Fund Management Co., Ltd.as of 30 Jun 2025256.98k0.34%
Maxwealth Fund Management Co., Ltd.as of 30 Jun 2025226.83k0.30%
Rongtong Fund Management Co., Ltd.as of 30 Jun 2025225.76k0.30%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.